炎症性肠病患者抗抑郁药使用情况:一项全国代表性人群研究
基于英国临床实践研究数据链,纳入2004至2016年14525例新发炎症性肠病(IBD)患者与按年龄性别1:4匹配的58027例对照。IBD患者抗抑郁药使用12年间增加51%,确诊后一年启动抗抑郁药的可能性较对照高34%(aHR 1.34,95%CI 1.21-1.49)。67%的用药者疗程短于国际指南推荐时长,其中34%治疗仅1个月或更短。
要点
- IBD确诊后一年内启动抗抑郁药的风险较对照高34%(aHR 1.34,95%CI 1.21-1.49)。
- 67%的IBD抗抑郁药使用者疗程短于国际指南推荐,34%治疗≤1个月。
- 18-24岁患者1个月内停药风险为40-60岁者的2.03倍(aHR 2.03,95%CI 1.40-2.95)。
核心结论
- IBD确诊后一年内启动抗抑郁药的可能性显著高于对照,但多数患者疗程短于国际指南推荐。
- 作者认为更好地整合医疗服务可能有益于合并精神疾病的IBD患者。
研究设计与样本
- 基于临床实践研究数据链的全国代表性人群研究,纳入2004至2016年14525例新发IBD病例,与按年龄和性别1:4匹配的58027例对照比较。
- 排除三环类抗抑郁药后,采用Cox回归分析抗抑郁药使用风险,采用logistic回归分析抗抑郁药治疗不足风险。
主要发现
- 12年研究期间IBD患者抗抑郁药使用增加51%。
- IBD患者确诊后一年启动抗抑郁药的可能性较对照高34%(aHR 1.34,95%CI 1.21-1.49)。
- 启动抗抑郁药的IBD患者中67%疗程短于国际指南推荐时长,其中34%治疗1个月或更短。
- 18-24岁患者1个月内停药可能性为40-60岁者的2.03倍(aHR 2.03,95%CI 1.40-2.95)。
- 社会经济剥夺与早期停药相关(aHR 1.40,95%CI 1.07-1.83)。
关键数值与推荐
- IBD患者确诊后一年启动抗抑郁药的aHR为1.34(95%CI 1.21-1.49)。
- 67%的IBD抗抑郁药使用者疗程短于国际指南推荐时长,34%治疗1个月或更短。
- 18-24岁患者1个月内停药的aHR为2.03(95%CI 1.40-2.95),参照组为40-60岁。
- 社会经济剥夺与早期停药的aHR为1.40(95%CI 1.07-1.83)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite high rates of depression and anxiety, little is known about the use of antidepressants amongst individuals diagnosed with inflammatory bowel disease (IBD). AIMS: To evaluate temporal trends in the use of antidepressants; rates of antidepressant initiation and adherence of antidepressant use to international guidelines amongst individuals with IBD. METHODS: This is a study of 14,525 incident IBD cases from 2004 to 2016 compared with 58,027 controls matched 1:4 for age and sex from the Clinical Practice Research Datalink. After excluding tricyclic antidepressants, we performed a Cox regression analysis to determine the risk associated with antidepressant use and logistic regression analysis to determine risk associated with antidepressant undertreatment. RESULTS: Antidepressant use amongst individuals with IBD increased by 51% during the 12-year study period, who were 34% more likely to initiate antidepressants in the year after IBD diagnosis compared with controls (aHR:1.34, 95% CI 1.21-1.49). In those with IBD starting antidepressants, 67% received treatment lasting less than the duration recommended in international guidelines, of which 34% were treated for 1 month or less. 18-24 year olds were twice as likely to discontinue treatment within 1 month compared with those aged 40-60 years (aHR:2.03, 95% CI 1.40-2.95). Socioeconomic deprivation was also associated with early treatment discontinuation (aHR:1.40, 95% CI 1.07-1.83). CONCLUSIONS: In the year following IBD diagnosis individuals are significantly more likely to start antidepressants compared with controls, but treatment duration fell short of recommendations in the majority. Better integration of services may benefit individuals with IBD and psychiatric comorbidity.
引用
- Jayasooriya N, Blackwell J, Saxena S, et al. Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study. Aliment Pharmacol Ther. 2022. PMID: 35244961. doi:10.1111/apt.16820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。